Table 4. Total and serious AEFI reporting rates for COVID-19 vaccines in non-PICs and PICs in the Western Pacific Region by vaccine type,a 1 March 2021–31 March 2022.
| Vaccine |
Total AEFIs n (rate per 100 000 doses) |
Serious AEFIs n (rate per 100 000 doses) |
|||||
|---|---|---|---|---|---|---|---|
| Total | Non-PICs | PICs | Total | Non-PICs | PICs | ||
|
mRNA
vaccine |
Pfizer- BioNTech |
465 901 (107.7) |
465 272 (107.7) |
629 (80.3) |
23 163 (5.9) |
23 100 (5.9) |
63 (8.1) |
| Moderna | 191 009 (187.7) |
190 894 (188.1) |
115 (42.0) |
4078 (4.2) |
4059 (4.2) |
19 (6.9) |
|
| Adenovirus vector-based vaccine | AstraZeneca | 229 331 (333.9) |
227 717 (335.3) |
1614 (209.1) |
7401 (13.5) |
7374 (13.6) |
27 (3.5) |
| Johnson & Johnson | 13 621 (128.1) |
13 405 (126.9) |
216 (324.1) |
1135 (10.7) |
1128 (10.7) |
7 (10.9) |
|
| Gamaleya | 875 (71.3) |
875 (71.3) |
0 | 37 (3.0) |
37 (3.0) |
0 | |
| Inactivated vaccine | Sinopharm | 8575 (46.3) |
8470 (45.9) |
105 (155.4) |
107 (0.6) |
106 (0.6) |
1 (1.5) |
| Sinovac | 42 670 (43.8) |
42 670 (43.8) |
0 | 4885 (5.0) |
4885 (5.0) |
0 | |
| Protein subunit | Novavaxb | 728 (281.3) |
728 (281.3) |
0 | 15 (8.6) |
15 (8.6) |
0 |
AEFI: adverse event following immunization; PICs: Pacific island countries and areas.
a In cases where either the numerator (number of events) or the denominator (number of doses administered) was not available separately (i.e. disaggregated by vaccine), or where there were no available data, data were excluded from computation of the AEFI rates.
b The rollout of the Novavax vaccine in the Western Pacific Region started in mid-February 2022, and by the end of March 2022, three countries were using the vaccine (cumulative total number of doses administered = 258 834).